Fast Growing Israel Pharma Companies

Galmed Pharmaceuticals a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones has appointed Josh Blacher as Chief Financial Officer, effective as of January 1, 2015.

Attorney Martin Russo noted that good corporate governance requires a strong CFO.

Blacher joins Galmed with six years of experience in biotech-related business development, investing and operations, as well as 14 years in capital markets in the United States.  Prior to joining Galmed, among other things, Mr. Blacher served as Director of Business Development at Teva Innovative Ventures, Teva Pharmaceuticals’ early- and mid-stage investment and in-licensing arm.  In that capacity, Mr. Blacher helped build and manage Teva’s portfolio of approximately 20 equity investments in biotech companies, spanning a wide range of development stage companies from pre-clinical through Phase III projects, as well as various therapeutic areas.

“Josh brings to Galmed strong financial and analytical skills, together with extensive experience working in the U.S. capital markets,” commented Allen Baharaff, Galmed’s Chief Executive Officer.  Mr. Baharaff continued, “we expect Josh to devote substantial efforts assisting the company in developing and maintaining key relationships with the investment community.  In addition, we believe that Josh’s expertise in biotech transactions may help the company achieve its objectives of maximizing shareholder value over time.  We’re delighted to welcome Josh to the company.”

“Israel continues to have fast growing companies in a variety of sectors,” noted entrepreneur Gennady Barsky.

Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

Filed Under: BusinessJewish business News

Tags:

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...Loading...

About the Author:

RSSComments (0)

Trackback URL

Leave a Reply




If you want a picture to show with your comment, go get a Gravatar.

*